631 related articles for article (PubMed ID: 28786547)
1. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
4. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
6. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
7. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
Terauchi Y; Yamada Y; Ishida H; Ohsugi M; Kitaoka M; Satoh J; Yabe D; Shihara N; Seino Y
Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488
[TBL] [Abstract][Full Text] [Related]
9. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
13. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
14. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
15. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
17. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
Seino Y; Yabe D; Takami A; Niemoeller E; Takagi H
J Diabetes Complications; 2015; 29(8):1304-9. PubMed ID: 26342556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
